Drug Trial Radar · NCT07663032
A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young Adults
Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
196
Planned (sponsor's estimate)
Start
Jun 24, 2026
Primary completion
Nov 14, 2027
Study completion Nov 14, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jun 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The current clinical study will evaluate the GVGH Quadrivalent Pan-Salmonella vaccine for the first time in healthy adults in Africa. The purpose of the current Phase 1 study is to evaluate the safety, reactogenicity, and the immune response induced by the Pan-Salmonella vaccine.
Conditions
- Salmonella Infections
Interventions
Pan-Salmonella-with-Alum (Low dose) vaccineBiological
Participants receive low dose of the Pan-Salmonella-with-Alum.
Pan-Salmonella-with-Alum (Full dose) vaccineBiological
Participants receive full dose of the Pan-Salmonella-with-Alum.
Pan-Salmonella-without-Alum (Low dose) vaccineBiological
Participants receive low dose of the Pan-Salmonella-without-Alum.
Pan-Salmonella-without-Alum (Full dose) vaccineBiological
Participants receive full dose of the Pan-Salmonella-without-Alum.
Typhoid Vi conjugate vaccineBiological
Participants receive Typhoid Vi conjugate vaccine as control
PlaceboOther
Participants receive Placebo (saline solution) as control.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with solicited administration site eventsTime frame: From Day 1 to Day 7
- Number of participants with solicited administration site eventsTime frame: From Day 61 to Day 67
- Number of participants with solicited administration site eventsTime frame: From Day 181 to Day 187
- Number of participants with solicited systemic eventsTime frame: From Day 1 to Day 7
- Number of participants with solicited systemic eventsTime frame: From Day 61 to Day 67
- Number of participants with solicited systemic eventsTime frame: From Day 181 to Day 187
- Number of participants with unsolicited eventsTime frame: From Day 1 to Day 30
- Number of participants with unsolicited eventsTime frame: From Day 61 to Day 91
- Number of participants with unsolicited eventsTime frame: From Day 181 to Day 211
- Number of participants with serious adverse events (SAEs)Time frame: From Day 1 to Day 211
- Number of participants with adverse events (AEs) or SAEs leading to withdrawal from the study or discontinuation of study interventionTime frame: From Day 1 to Day 211
- Number of participants with changes from baseline or changes from normal values for hematological, renal, and hepatic panels test resultsTime frame: At Day 8
- Number of participants with changes from baseline or changes from normal values for hematological, renal, and hepatic panels test resultsTime frame: At Day 68
- Number of participants with changes from baseline or changes from normal values for hematological, renal, and hepatic panels test resultsTime frame: At Day 188
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Bloemfontein, South Africa · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.